Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc.

<< Previous

Bullboard Posts

Next >>

Post by StockHawk1on Oct 12, 2022 5:18pm

135 Views

Post# 35020748

AGN.c gets $450 cash rebate💰💰

Due to Algernon Pharmaceuticals' (AGN.c AGNPF) strategic choice of Australia as a research location the pharma tech company has received another cash refund from an Australian tax credit program.

This refund was to the tune of $450K bringing AGN's refunds to date to over $3.0M

Today AGN closed up @ $3.45

MC $8.494M

https://www.globenewswire.com/news-release/2022/09/21/2520035/0/en/Algernon-Pharmaceuticals-Announces-Receipt-of-CDN-450K-Cash-Refund-from-Australian-Research-Program.html

<< Previous

Bullboard Posts

Next >>

3 Mid-Sized Stocks to Consider This Season